... with $7M in the bank and estimated cash burn under $4M next quarter, including $250K for exploration.This cash situation does not allow any more delay or nasty legal battles.Holding my breath.
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%